Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...
(RTTNews) - Avadel Pharmaceuticals plc (AVDL), Tuesday revealed that 94 percent of patients in RESTORE study with narcolepsy preferred the once-nightly regimen of Lumryz over twice-nightly Oxybate ...
Post-hoc analysis from pivotal Phase 3 REST-ON trial confirmed the efficacy of LUMRYZ in study participants who were and were not using a stable dose of an alerting agent – – Baseline data ...
DUBLIN - Avadel Pharmaceuticals plc (NASDAQ:AVDL) released final data from their RESTORE study, indicating a strong preference for their once-nightly narcolepsy medication, LUMRYZ, over traditional ...
Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21 ...
Some results have been hidden because they may be inaccessible to you